PRaG therapy for advanced solid tumors
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new way to combine two types of radiation therapy (called PRaG-1 and PRaG) for people with advanced solid tumors that have few treatment options. The goal is to see if this approach can help your immune system fight the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced solid tumor cancer that has come back or spread, and no standard treatments are available or you cannot tolerate them.
- Your lymphocyte count (a type of white blood cell) is lower than normal.
- You do not have serious heart problems, active infections, or immune system disorders that would make the trial unsafe.
- You have not had another cancer in the last 5 years (except certain skin cancers or early cervical cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called PRaG-1 that helps your immune system fight cancer. It is for people with advanced cancer who are generally healthy and do not have serious heart or immune problems.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
This trial tests a precise type of radiation therapy (PRaG) for people aged 75 and older whose cancer has spread or cannot be treated with standard options. The goal is to see if this treatment can help control the tumor and improve quality of life.
This trial tests a new combination treatment (PRaG therapy) for patients with locally advanced pancreatic cancer that has not spread. It aims to help shrink the tumor so it can be removed surgically, and it is for patients who have not had prior radiation, chemotherapy, or immunotherapy.
This trial tests how safe PRJ1-3024 is and how the body handles it, and it also looks for early signs that it can shrink advanced solid tumors. It may help people whose cancer can’t be treated with standard options.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Lymphopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.